Atossa Genetics (NASDAQ:ATOS) Stock Price Crosses Below 200-Day Moving Average – Should You Sell?

Atossa Genetics Inc. (NASDAQ:ATOS)’s share price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.42 and traded as low as $1.81. Atossa Genetics shares last traded at $1.83, with a volume of 466,738 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on ATOS shares. Weiss Ratings cut shares of Atossa Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Ascendiant Capital Markets reduced their price target on shares of Atossa Genetics from $120.00 to $24.00 and set a “buy” rating on the stock in a research report on Friday, April 10th. Finally, HC Wainwright upped their price objective on shares of Atossa Genetics to $25.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $24.50.

Atossa Genetics Price Performance

The stock has a 50 day moving average price of $4.74 and a two-hundred day moving average price of $6.42. The company has a market capitalization of $15.76 million, a price-to-earnings ratio of -0.57 and a beta of 1.24.

Atossa Genetics (NASDAQ:ATOS) last issued its quarterly earnings results on Friday, May 8th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.12). Sell-side analysts forecast that Atossa Genetics Inc. will post -4.3 EPS for the current fiscal year.

Hedge Funds Weigh In On Atossa Genetics

A number of large investors have recently modified their holdings of the stock. Geode Capital Management LLC grew its stake in shares of Atossa Genetics by 0.7% during the fourth quarter. Geode Capital Management LLC now owns 1,371,909 shares of the company’s stock valued at $810,000 after purchasing an additional 9,627 shares during the last quarter. Hudson Bay Capital Management LP bought a new position in Atossa Genetics in the 2nd quarter worth approximately $26,000. JPMorgan Chase & Co. lifted its holdings in Atossa Genetics by 1,294.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 38,215 shares of the company’s stock worth $33,000 after buying an additional 35,474 shares in the last quarter. Bank of America Corp DE lifted its holdings in Atossa Genetics by 55.7% during the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock worth $83,000 after buying an additional 35,629 shares in the last quarter. Finally, &PARTNERS acquired a new position in Atossa Genetics during the 4th quarter worth $25,000. 12.74% of the stock is currently owned by institutional investors and hedge funds.

About Atossa Genetics

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.